Hepatitis C Caring
Ambassadors Program Newsletter
August 2005
In The News
Old View Slows Hepatitis C Fight (New Zealand)
http://www.rednova.com/news/health/192556/old_view_slows_hepatitis_c_fight/
4 Million People in Bangladesh Suffering From Hepatitis C Virus
Genelabs Drug Discovery Team Advances Compounds Against the Hepatitis C Virus in Preclinical Development
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-04-2005/0004082446&EDATE=
While Hep C infections climb dramatically, a downtown Hep C clinic struggles to find funding
http://www.zwire.com/site/news.cfm?newsid=14972579&BRD=2318&PAG=461&dept_id=484045&rfi=6
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus
http://www.rxpgnews.com/research/pharmacology/article_2010.shtml
Anadys Pharmaceuticals Announces Publication of Clinical Study of Isatoribine in Chronic Hepatitis C Demonstrating Proof of Concept
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-23-2005/0004092747&EDATE=
Star's fight for life
http://entertainment.news.com.au/story/0,10221,16367055-7485,00.html
Reuse of syringes to withdraw saline from a common bag resulted in a massive outbreak of 99 new HCV infections at an independent hematology/oncology clinic in Nebraska
http://www.clinicaloptions.com/hep/news/news_imed_392.asp
High-risk behaviors and increasing time of incarceration contribute to high prevalence of HCV infection in the prison population
Most chronic hepatitis C sufferers will develop cirrhosis in later life. Study suggests cirrhosis and liver disease nearly inevitable for people with hep C
http://www.eurekalert.org/pub_releases/2005-09/aga-mch083105.php
A study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt.
http://i-newswire.com/pr44319.html
Study: Injection Drug Use is Main HCV Risk in HIV
http://www.hepatitisneighborhood.com/content/in_the_news/archive_2484.aspx
Hepatitis A Vaccine Urged for Hep C Patients
http://www.foxnews.com/story/0,2933,166661,00.html
Hepatitis C co-infection blunts response to antiretroviral therapy
http://www.aidsmap.com/en/news/6B6EC4F2-C5C6-43AB-93C1-A9836498851F.asp
Nurse Shares Story of Hepatitis C, the 'Silent Epidemic'
http://www.ksdk.com/news/health_article.aspx?storyid=83561
[California] Senate Approves Needle-Exchange bill http://www.ukiahdailyjournal.com/Stories/0,1413,91~3089~3024165,00.html
Migenix to test hepatitis C drug
http://www.pharmaceutical-business-review.com/article_news.asp?guid=3595201E-8F70-4B24-A519-0C176EE1E679
HIV-positive patients coinfected with HCV up to 80% more likely to die even with HIV treatment
http://www.aidsmap.com/en/news/812944F5-6A70-4F45-A1C9-229FCEA3420C.asp
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Everson GT, et al. Hepatology. 2005 Aug;42(2):255-62.
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. von Wagner M, et al. Gastroenterology. 2005 Aug;129(2):522-7.
Hepatitis B virus DNA
integration in hepatocellular carcinoma after interferon-induced disappearance
of hepatitis C virus. Tamori A, et al. Am J Gastroenterol. 2005
Aug;100(8):1748-53.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086711&query_hl=7
Growth in the First 5
Years of Life is Unaffected in Children with Perinatally-acquired Hepatitis C
Infection. European Paediatric Hcv Network. . J Pediatr.
2005 Aug;147(2):227-32
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16126055&query_hl=7
Diagnostic Discordance for
Hepatitis C Virus Infection in Hemodialysis Patients. Kalantar-Zadeh K, Miller LG, Daar ES. Am J Kidney Dis. 2005
Aug;46(2):290-300.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16112048&query_hl=7
Efficacy and tolerability of peginterferon alpha-2a with or without
ribavirin in thalassaemia major patients with chronic hepatitis C virus
infection. Inati A, et al. Br J Haematol. 2005
Aug;130(4):644-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16098081&query_hl=7
Is interferon-alpha therapy safe and effective for patients with chronic hepatitis
C and inflammatory bowel disease? A case-control study. Bargiggia S, et al. Aliment Pharmacol Ther.
2005 Aug 1;22(3):209-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16091058&query_hl=7
Mood Alterations During Interferon-Alfa Therapy in Patients With Chronic
Hepatitis C: Evidence for an Overlap Between Manic/Hypomanic and Depressive
Symptoms. Constant A, et al. J Clin Psychiatry. 2005
Aug;66(8):1050-1057.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086622&query_hl=7
International, multicenter, randomized, controlled study comparing
dynamically individualized versus standard treatment in patients with chronic
hepatitis C.
Zeuzem S, et al. J Hepatol. 2005
Aug;43(2):250-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16082736&query_hl=9
Clinical presentation of
chronic hepatitis C in patients with end-stage renal disease and on
hemodialysis versus those with normal renal function. Hu KQ, et al. Am J Gastroenterol. 2005
Sep;100(9):2010-8.
http://amedeo.com/p2.php?id=16128946&s=chep
Serum alpha-fetoprotein
levels in patients with advanced hepatitis C: results from the HALT-C Trial.
Di Bisceglie AM, et. al. J. Hepatol. 2005
Sep;43(3):434-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16136646&dopt=Abstract
Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Piche T, et al. Gut. 2005 Aug;54(8):1169-73.
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Lok AS, et al. Hepatology. 2005 Aug;42(2):282-92.
Basic and Applied Science, Pre-Clinical Studies
Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Tang KH, et al. J Hepatol. 2005 Aug 31; [Epub ahead of print]
Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells. Dansako H, Naka K, Ikeda M, Kato N. Biochem Biophys Res Commun. 2005 Aug 30; [Epub ahead of print]
Anterior cingulate activation and error processing during interferon-alpha treatment. Capuron L, et. al. Biol Psychiatry. 2005 Aug 1;58(3):190-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16084839&query_hl=7
Mutagenic effects of ribavirin and response to interferon/ribavirin
combination therapy in chronic hepatitis C. Asahina Y, Izumi N, et al. J Hepatol. 2005
Oct;43(4):623-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16098627&query_hl=7
Hepatitis C Virus Genotype
1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American
and White Patients. Layden-Almer JE, et al. J Infect Dis. 2005 Sep
15;192(6):1078-87. Epub 2005 Aug 12.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107963&query_hl=7
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. Waris G, Siddiqui A. J Virol. 2005 Aug;79(15):9725-34.
Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. Abdalla MY, et al. J Med Virol. 2005 Aug;76(4):489-97.
Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. Garcia-Mediavilla MV, et al. J Hepatol. 2005 Oct;43(4):606-13.
The Expression of BCL-2 in Chronic Liver Diseases. Mutluay R, et al. Saudi Med J. 2005 Aug;26(8):1245-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16127523&query_hl=7
Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. Starkel P, De Saeger C, Leclercq I, Strain A, Horsmans Y. J Hepatol. 2005 Oct;43(4):687-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16098628&query_hl=7
CD8+ T Cell Depletion Amplifies Hepatitis C Virus Replication in Peripheral
Blood Mononuclear Cells. Li Y, et al. J Infect Dis. 2005 Sep
15;192(6):1093-101. Epub 2005 Aug 10.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107965&query_hl=7
Modulation of Vaccine-Induced Immune Responses to Hepatitis C Virus in
Rhesus Macaques by Altering Priming before Adenovirus Boosting. Rollier C., et al. J Infect Dis. 2005 Sep
1;192(5):920-9. Epub 2005 Aug 1.
In vitro studies of cross-resistance mutations against two hepatitis C virus
serine protease inhibitors, VX-950 and BILN 2061. Lin C J., et al. Biol Chem. 2005 Aug 8; [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16087668&query_hl=7
Interdomain communication in hepatitis C virus polymerase abolished by small
molecule inhibitors bound to a novel allosteric site. Di Marco S, et al. J Biol Chem. 2005 Aug
19;280(33):29765-70. Epub 2005 Jun 13.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15955819&query_hl=10
Reduction of serum ghrelin concentration during interferon-alpha therapy in patients with chronic hepatitis C. Watanabe H, et al. Hepatol Res. 2005 Aug 18; [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16112898&query_hl=7
HIV/HCV Coinfection
Failure of Hepatitis C
Therapy in HIV-Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus
Genotype. Soriano V, et al. J Infect Dis. 2005 Oct
1;192(7):1245-8. Epub 2005 Aug 24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16136468&query_hl=7
Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple
noninvasive indexes. Macias J, et al. Gut. 2005 Aug 23; [Epub ahead
of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16118349&query_hl=7
Hepatitis C virus infection in HIV type 1-infected individuals does not
accelerate a decrease in the CD4+ cell count but does increase the likelihood
of AIDS-defining events. Stebbing J, et al. Clin Infect Dis. 2005 Sep
15;41(6):906-11. Epub 2005 Aug 5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107994&query_hl=7
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B
co-infection. Hui CK, et al. J Clin Virol. 2005 Aug 12;
[Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16103008&query_hl=7
Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and
Response to Highly Active Antiretroviral Therapy. Rockstroh JK, et al. J Infect Dis. 2005 Sep
15;192(6):992-1002. Epub 2005 Aug 11.
Hepatitis C infection is not associated with systemic HIV-associated
non-Hodgkin's lymphoma: a cohort study. Waters L, et al. Int J Cancer. 2005 Aug
10;116(1):161-3.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15756687&query_hl=10
Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. Backus LI, et al. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-9.
Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Monto A, et al. Hepatology. 2005 Aug;42(2):310-6.
Complementary and Alternative Therapies
Non-interferon-based
therapy: an option for amelioration of necro-inflammation in hepatitis C
patients who cannot afford interferon therapy. El-Zayadi AR, et al. Liver Int. 2005
Aug;25(4):746-51.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086711&query_hl=7
Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. Ko WS, et al. World J Gastroenterol. 2005 Aug 14;11(30):4697-702.
Miscellaneous Works
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Morrill JA, Shrestha M, Grant RW. J Gen Intern Med. 2005 Aug;20(8):754-8.
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Campbell JV, et al. Drug Alcohol Depend. 2005 Aug 26; [Epub ahead of print]
Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Mathei C, et al. Eur J Clin Microbiol Infect Dis. 2005 Aug 19; [Epub ahead of print]
Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum. De Cock L, Hutse V, Vranckx R. Eur J Clin Microbiol Infect Dis. 2005 Aug 19; [Epub ahead of print]
Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Wang B, et al. Transfusion. 2005 Jul;45(7):1089-96.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15987352&query_hl=2
Geospatial analysis of
hepatitis C in Connecticut: a novel application of a public health tool.
Trooskin SB, Hadler J, St Louis T, Navarro et al. VJ. Public Health.
2005 Aug 4; [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16084545&query_hl=7
Patients' Experiences
Related to Anti-viral Treatment for Hepatitis C. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patient Educ Couns. 2005 Aug 9;
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16098705&query_hl=7
Prospective multicenter
study of eligibility for antiviral therapy among 4,084 U.S. veterans with
chronic hepatitis C virus infection. Bini EJ, et al. Am J Gastroenterol.
2005 Aug;100(8):1772-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086714&query_hl=7
An assessment of hepatitis
C virus infection among health-care workers of the National Cancer Institute of
Naples, Southern Italy. Montella M, et al. Eur J Public Health. 2005
Jul 21; [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16037074&query_hl=3
Determining the Extent of Quality Health Care for Hospitalized Patients with
Cirrhosis. Talwalkar JA. Hepatology. 2005
Aug;42(2):492-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15942950&query_hl=10.
Cost comparison of two combination therapies with peginterferon alfa and
ribavarin for the treatment of hepatitis C [Article in German] Telser H, Mulhaupt B, Helbling B, Zweifel P. Schweiz Rundsch Med Prax. 2005 Aug
10;94(32):1207-14.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16128208&query_hl=7
Intrafamilial transmission
of hepatitis C in Egypt. Mohamed MK, et al. Hepatology. 2005 Jul 19;
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16032698&query_hl=2
ICSI for treatment of human immunodeficiency virus and hepatitis C virus-serodiscordant couples with infected male partner. Mencaglia L, et al. Hum Reprod. 2005 Aug;20(8):2242-6. Epub 2005 Jun 9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15946998&query_hl=10
Community incidence of hepatitis B and C among reincarcerated women. Macalino GE, et al. Clin Infect Dis. 2005 Oct 1;41(7):998-1002. Epub 2005 Aug 30.
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Colletta C, et al. Hepatology. 2005 Aug 24; [Epub ahead of print]
Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. Laperche S, et al. J Clin Microbiol. 2005 Aug;43(8):3877-83.
Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. Gerard C, et al. J Med Virol. 2005 Aug;76(4):503-10.